Author: Ananda Public Affairs

GREENWOOD VILLAGE, Colo. and LOS ANGELES, (PRNewswire)   ANANDA Scientific Inc., a research focused bio-pharmaceutical company today announced the first patient enrolled in the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. (Clinical Trials.gov Identifier: NCT03787628)   This trial is being led by principal investigators Edythe… Continue reading ANANDA Scientific Announces First Patient Enrolled in the Clinical Trial on the Treatment of Opioid Use Disorder (OUD)

OMAHA, Neb. & GREENWOOD VILLAGE, Colo. — (BUSINESS WIRE)   The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc announce a collaboration in a new clinical trial investigating treatment for adults with Post-Traumatic Stress Disorder (PTSD).   The trial is being led by principal investigator Mathew Rizzo, M.D., the Reynolds Professor and chair… Continue reading University of Nebraska Medical Center and ANANDA Scientific announce FDA approval of the IND for a Clinical Trial exploring Treatment for Post-Traumatic Stress Disorder (PTSD)

GREENWOOD VILLAGE, Co and New York, NY — (BUSINESS WIRE) – ANANDA Scientific Inc., a biotech pharmaceutical company, and NYU Grossman School of Medicine today announced that the first patient has been enrolled in a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology. This trial is… Continue reading ANANDA Scientific and NYU Grossman School of Medicine Announce First Patient enrolled in the Clinical Trial for Opioid Sparing in Participants with Radiculopathic Pain.

GREENWOOD VILLAGE, Colo. & LOS ANGELES , CA — (BUSINESS WIRE) – ANANDA Scientific Inc., (a biotech pharma company) today announced approval by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology… Continue reading ANANDA Scientific Announces FDA approval of the IND for the Clinical Trial on the Treatment of Opioid Use Disorder (OUD)

GREENWOOD VILLAGE, Colo. & NEW YORK (BUSINESS WIRE) – ANANDA Scientific Inc., a biotech pharma company, announced a clinical trial to evaluate Nantheia™ ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology for Opioid Use Disorder. An Investigational New Drug (IND) application has been approved by the U.S. Food and Drug… Continue reading ANANDA Scientific’s Liquid Structure™ Cannabidiol (CBD) to be clinically evaluated for Opioid Use Disorder.

GREENWOOD VILLAGE, Colo. & LOS ANGELES, CA (BUSINESS WIRE) – ANANDA Scientific Inc., a biotech pharma company, today announced the commencement of a clinical trial to be done in collaboration with the Jane and Terry Semel Institute at David Geffen School of Medicine at UCLA, to evaluate Nantheia™ ATL5, an investigational drug using cannabidiol (CBD)… Continue reading ANANDA Scientific and the David Geffen School of Medicine UCLA Announce a Clinical Trial Utilizing Liquid StructureTM Cannabidiol (CBD) for the Treatment of Opioid Use Disorder (OUD).

GREENWOOD VILLAGE, Colo. & NEW YORK (BUSINESS WIRE) – ANANDA Scientific Inc., a biotech pharmaceutical company, and NYU Grossman School of Medicine today announced that the first patient has been enrolled in a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology as a treatment for Post-Traumatic… Continue reading ANANDA Scientific and NYU Grossman School of Medicine Announce First Patient Enrolled in the Clinical Trial Evaluating Liquid Structure™ Cannabidiol (CBD) for Treatment of Post-Traumatic Stress Disorder (PTSD)

GREENWOOD VILLAGE, Colo. & NEW YORK (BUSINESS WIRE) – ANANDA Scientific Inc., a biotech pharma company, and NYU Grossman School of Medicine today announced a second clinical trial to evaluate the effect of cannabidiol in ANANDA’s proprietary delivery technology on opioid sparing in participants with chronic radiculopathic pain syndromes maintained on opioid therapy. An Investigational… Continue reading Cannabidiol (CBD) and Chronic Radiculopathic Pain Syndromes


GREENWOOD, Colo. & NEW YORK, January 12, 2021 – ANANDA Scientific Inc., a biotech pharma company, and NYU Grossman School of Medicine today announced a new clinical trial evaluating the efficacy of cannabidiol in ANANDA’s proprietary delivery technology as a treatment for Post-Traumatic Stress Disorder (PTSD) symptoms and Neurocognitive Impairment in patients with PTSD and… Continue reading Cannabidiol (CBD) for Treatment of
 Post-Traumatic Stress Disorder (PTSD)